Peripheral T Cell Lymphoma
Oncology
2
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Bristol Myers SquibbPRINCETON, NJ
1 program1
NivolumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Acrotech BiopharmaBelinostat Injection
Bristol Myers SquibbNivolumab
Clinical Trials (2)
Total enrollment: 18 patients across 2 trials
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Start: Oct 2023Est. completion: Nov 2030
Phase 3Recruiting
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
Start: Nov 2018Est. completion: Sep 202218 patients
Phase 1/2Completed
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
2h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
2h ago
Office Administrator
SystImmune
2h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
3h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
3h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
3h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 18 patients
Monoclonal Antibody is the dominant modality (100% of programs)
3 companies competing in this space